| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4284351 | Current Surgery | 2006 | 4 Pages |
Abstract
Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
John H. Heinzerling, Sergio Huerta,